Enlicitide for Healthy Participants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how the body processes different types of enlicitide, a medication, under various conditions, such as after a high-fat meal or on an empty stomach. Participants will receive one of several enlicitide formulations to observe how each behaves in the body. The study seeks healthy individuals with a BMI between 18 and 32 who have no history of serious digestive issues, cancer, or certain infections like HIV or hepatitis. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new medication.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
A previous study did not provide specific safety information for enlicitide. As this is an early-phase trial, the main goal is to assess the treatment's safety for people. Early-phase trials typically serve as the initial step in testing a new treatment in humans. These trials help determine the treatment's safety and the appropriate dose. Researchers closely monitor participants for any side effects or unexpected medical issues. This careful observation helps gather important safety information about the treatment.12345
Why are researchers excited about this trial's treatments?
Enlicitide is unique because it is an investigational treatment being explored for its different formulations and how they perform under fed and fasted conditions. Unlike typical treatments that may not specify dietary conditions, enlicitide's trials are examining its effectiveness and absorption with or without a high-fat meal. Researchers are excited because understanding how enlicitide behaves in these conditions could lead to more personalized and effective dosing recommendations, potentially enhancing its efficacy and safety profile compared to existing options.
What evidence suggests that this trial's treatments could be effective?
Research has shown that enlicitide, a pill designed to lower bad cholesterol (LDL-C), works by blocking a protein called PCSK9, which typically maintains high cholesterol levels. Studies have found that regular use of enlicitide can reduce LDL-C levels by 57–65%. This treatment matches the effectiveness of injectable medications but offers the convenience of a pill. As a result, it presents a promising option for managing cholesterol. In this trial, participants will receive different formulations of enlicitide under various conditions to evaluate its effectiveness and safety.678910
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for healthy adults with a BMI between 18.0 and 32.0 who do not have any significant health problems.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of enlicitide under fed and fasted conditions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Enlicitide
Trial Overview
Researchers are studying how different types of the drug enlicitide behave in the body when taken by healthy people, both on an empty stomach and after eating a high-fat meal.
How Is the Trial Designed?
5
Treatment groups
Experimental Treatment
Participant will receive a single oral dose of enlicitide formulation test 2 under fasted conditions.
Participants will receive a single oral dose of enlicitide formulation test 2 after a high-fat breakfast.
Participants will receive a single oral dose of enlicitide formulation test 1 under fasted conditions.
Participants will receive a single oral dose of enlicitide formulation test 1 after a high-fat breakfast.
Participants will receive a single oral dose of enlicitide reference formulation.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
Emerging oral therapeutic strategies for inhibiting PCSK9 - PMC
Pharmacokinetics properties Oral administration of enlicitide decanoate is formulated with permeation enhancers. When fasted participants were ...
Orally Bioavailable Macrocyclic Peptide That Inhibits ...
Pharmacokinetics. When fasted participants were dosed orally with 10 to 300 mg of MK-0616 formulated with the PE Labrasol, the increases in the ...
Merck's Enlicitide Decanoate, an Investigational Oral ...
Enlicitide has the potential to be the first approved oral PCSK9 inhibitor. It is designed to lower LDL-C via the same biological mechanism as ...
Enlicitide (Lipfendra): the first oral PCSK9 inhibitor
A dedicated phase 1 study found no clinically meaningful effect of enlicitide on the pharmacokinetics of co- administered narrow therapeutic ...
Enlicitide Decanoate - Peptide Research | APS
This innovative molecule is under development as a therapeutic for atherosclerotic cardiovascular disease, ASCVD, Its high oral bioavailability ...
Strategies designed to help healthcare professionals ...
There is no strong evidence for any single strategy to help healthcare professionals to recruit participants in research studies.
Help finding missing participants
PBGC's Missing Participants Program connects people — missing when their pension plans terminated — to their retirement benefits.
Myocardial injury and ventricular dysfunction related to ...
Methods and results: We screened 60 nonelite participants, before and after the 2004 and 2005 Boston Marathons, with echocardiography and serum biomarkers.
FDA Selects Seven Participants for PreCheck Pilot ...
FDA announces the selection of seven companies to participate in the FDA PreCheck Pilot Program, a new initiative designed to boost American ...
Managing participants in a meeting
You can mute participants, control screen sharing, assign co-hosts, manage waiting rooms, and more. For information about meeting security, review available ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.